Dr Geoffrey Nichol joins Ikaria

pharmafile | June 22, 2010 | Appointment | Research and Development |  Ikaria, appointment, research and development 

US biotherapeutics company Ikaria has appointed Dr Geoffrey Nichol chief medical officer, with responsibility for its late-stage drug development activies.

“We are delighted to welcome Geoff, who will leverage his extensive experience in driving our late-stage assets forward,” commented Daniel Tasse, Ikaria’s chairman and chief executive.

“We believe he can help us achieve our vision of becoming a leader in critical care by driving the commercialisation process of our two late-stage product candidates, as well as the FDA approval process for the additional indications we are pursuing for our marketed product Inomax.”

Advertisement

Dr Nichol has over 20 years of experience in the pharmaceutical industry and joins Ikaria from Medarex, where he was senior VP of product development.

Prior to this he held several leadership positions at Novartis Pharmaceuticals, and began his industry career at SmithKline Beecham Pharmaceuticals.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content